Peptides for Cellulite: No Topical Peptide Trial, Two Oral Collagen Studies, and the Injectable That Was Withdrawn

Cellulite creams are one of the largest product categories in body care, searched about 4,000 times a month in the US, and "peptides for cellulite" is a growing sub-question (keyword data, October 2026). This page counts what has been tested, what was found, and what happened to the one cellulite drug FDA approved, as of 27 October 2026. It reports studies; it does not recommend a product or a treatment.

Why cellulite resists creams

Every trial paper read for this page describes the same anatomy. Under the skin, fat sits in lobules separated by fibrous bands called septae that run from the skin down to deeper tissue. Where the bands tether the skin while the fat between them pushes up, the surface takes on the dimpled "mattress" look. The phase 3 drug trials below put it plainly: fibrous septae "play a role in contour alterations associated with cellulite". A cream acts on the outer skin. The bands sit below it.

The census

PubMed, searched 27 October 2026, every title in the small sets read:

The finding: no trial of a peptide applied to the skin for cellulite exists in PubMed. The three peptide records are two oral collagen-peptide trials and a 2026 opinion article that links cellulite to metabolic health in the GLP-1 era. Body creams that list peptides make claims the indexed literature has not tested.

The two oral collagen-peptide trials

• Schunck, Zague, Oesser and Proksch, 2015 (Journal of Medicinal Food). Double-blind and placebo-controlled; 105 women aged 24 to 50 with moderate cellulite took 2.5 g a day of specific bioactive collagen peptides or placebo for six months. Cellulite scores fell and thigh-skin waviness was reduced in normal-weight women, and dermal density improved; the effect was smaller in overweight women, and the shortening of the dermis-fat border did not reach significance against placebo. Two authors are from the Collagen Research Institute in Kiel.
• Hwang et al., 2026 (Journal of Medicinal Food). Randomized and placebo-controlled; 114 women aged 20 to 50 with thigh cellulite and thinning hair took 1,000 mg a day of a low-molecular-weight fish collagen peptide for 24 weeks. Cellulite severity, the dermis-fat border, roughness and elasticity improved at weeks 12 and 24 against placebo. The first authors are from the health-food R&D department of NEWTREE Co., the ingredient's maker; the paper declares no competing interests.

Both reported positive results, both measured cellulite with imaging and scales rather than photographs alone, and both are tied to the ingredient business. Neither has been repeated by an unconnected group. These are oral supplements; their results say nothing about a peptide cream. The general collagen question is covered on peptides vs collagen.

What the cream trials showed

Of the 13 records, two are not about a cream at all (compression socks with ceramic particles, and ultrasound in multiple sclerosis). In the rest, the ingredients tested were caffeine, retinol and retinyl compounds, aminophylline, phosphatidylcholine, a forskolin-carnitine-retinol slimming mix and a hypertonic "osmotic" cream, several combined with light, radiofrequency, compression or massage devices that make the cream's own contribution impossible to separate.

The cleanest design is also the oldest: a 2000 left-right randomized trial of topical retinol (Piérard-Franchimont et al., American Journal of Clinical Dermatology). Fifteen women aged 26 to 44 who had asked for liposuction applied retinol to one thigh and a placebo cream to the other for six months, which cancels out the effect of massage. Elasticity rose 10.7% and viscosity fell 15.8% on the retinol side, but the authors report that "the lumpy-bumpy appearance of the skin showed either little response or was not responsive to the treatment". The best-designed cream trial, in other words, found a change in how skin behaved and not in the dimples.

A 1999 randomized trial in Plastic and Reconstructive Surgery set the tone in its own title: "Cellulite treatment: a myth or reality", testing mechanical massage and aminophylline cream.

The approved drug, and why it was withdrawn

The one medicine FDA approved for cellulite was not a cream. Qwo, collagenase clostridium histolyticum-aaes, is a mixture of bacterial enzymes that digest collagen, injected under the skin to loosen the septae. FDA approved it on 6 July 2020 (BLA 761146, Endo) for moderate to severe cellulite in the buttocks of adult women: up to 12 injections per buttock, three visits 21 days apart, per its label.

The two pivotal trials, RELEASE-1 and RELEASE-2 (Kaufman-Janette et al., Dermatologic Surgery, 2021), treated 843 women:

Every author was an Endo investigator, consultant, grant recipient, shareholder or employee, as the paper's conflict statement lists. The label's adverse-reaction table from the same trials shows the problem that followed: bruising in 84% of women given Qwo against 21% on placebo, pain 48% against 10%, nodules 33% against 1%, and discoloration 8% against 1%.

On 6 December 2022 Endo announced it would cease producing and selling Qwo "in light of market concerns about the extent and variability of bruising following initial treatment as well as the potential for prolonged skin discoloration", after an open-label study of ways to reduce bruising produced only modest effects. The company stated that Qwo remained FDA-approved. So the single cellulite drug to clear FDA review left the market within two and a half years, over the cosmetic side effect its own trials had recorded.

Off-label injectables

Some clinics use Sculptra or diluted Radiesse on the thighs and buttocks. Neither is approved for cellulite. For Sculptra, two small randomized trials measured cellulite (20 and 31 women; in the second, both arms also had subcision, a procedure that cuts the bands directly); they are set out with the rest of the body record on Sculptra for the buttocks, and Radiesse's diluted body use on hyperdilute Radiesse. Energy and suction devices are a separate category this page does not cover.

What this page did not do

It did not read and tabulate the ingredient lists of cellulite creams on sale tonight, so it makes no claim about how many declare a peptide or where in the list. That census is a separate job.

What can fairly be said

There is no trial of a peptide cream for cellulite. Two oral collagen-peptide trials, both tied to ingredient companies, reported less visible cellulite over six months. The best-designed cream trial found retinol changed skin elasticity but not the lumps. The one approved drug worked in a minority of women at the two-level threshold, bruised most of them, and was withdrawn by its maker. Anyone weighing a treatment should ask what it has been tested against and for how long, and take the question to a dermatologist. Related reading: peptides for loose skin and peptide body lotion.

Sources

Opened 27 October 2026: PubMed searches cellulite[tiab] (622), with randomized controlled trial[pt] (52), with topical, cream or gel terms (13, all titles read), with peptide*[tiab] (3, all read; tagged trials 2), with collagenase[tiab] (2), caffeine[tiab] (5), retinol[tiab] (3) and retracted publication[pt] (1); abstracts of PMIDs 33840781, 26561784, 41788055 and 11702613. openFDA Drugs@FDA, application BLA761146 (original approval 6 July 2020) and the QWO structured product label (indications, dosage, warnings, adverse reactions table; label effective 22 July 2022). Endo International plc, press release "Endo to Cease Production and Sale of Qwo", 6 December 2022, filed with the SEC as Exhibit 99.1 to Form 8-K; Endo Form 10-K for 2022. Search volume: DataForSEO clickstream-normalised estimates, United States, measured 26 October 2026. Corrections go to the contact page.